Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Respiratory Syncytial Virus (RSV) is a contagious viral pathogen causing severe respiratory tract infections, especially in infants, elderly populations, and immunocompromised patients. According to Jessy Joseph et al., 2025, RSV positivity rates in India vary between approximately 2%-62%. As per respiratory syncytial virus pipeline analysis by Expert Market Research, the pipeline is expanding with focus on monoclonal antibodies, antiviral therapies, and vaccines. Increasing R&D investment, rising disease burden, and unmet clinical needs are driving RSV treatment development and future market growth globally.
-
Major companies involved in the respiratory syncytial virus pipeline analysis include Shionogi Inc., Pulmotect, Inc., Blue Lake Biotechnology Inc., and others.
-
Leading drugs currently in the pipeline include S-337395, PUL-042, BLB-201, and others.
-
Rising respiratory syncytial virus burden in infants and older adults is accelerating development of monoclonal antibodies, mRNA vaccines, and antiviral therapies, supported by expanding clinical trials and regulatory approvals.
Report Coverage
The Respiratory Syncytial Virus Pipeline Analysis Report by Expert Market Research gives comprehensive insights into respiratory syncytial virus therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for respiratory syncytial virus. The respiratory syncytial virus report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The respiratory syncytial virus pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with respiratory syncytial virus treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to respiratory syncytial virus.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Respiratory Syncytial Virus Pipeline Outlook
Respiratory syncytial virus is a contagious respiratory virus that primarily affects infants, young children, and older adults. It spreads through respiratory droplets and direct contact with contaminated surfaces. Infection typically occurs during seasonal outbreaks in fall and winter. The virus causes inflammation in the airways, leading to bronchiolitis, pneumonia, and breathing difficulties, especially in high-risk populations.
Respiratory syncytial virus treatment focuses on supportive care, including oxygen therapy, hydration, and fever management. In severe cases, hospitalization may be required. Preventive options include monoclonal antibodies and vaccination strategies to reduce infection risk and disease severity. Beyfortus (nirsevimab-alip) demonstrated strong clinical efficacy in reducing respiratory syncytial virus (RSV) lower respiratory tract infections, as highlighted in the July 2023 FDA approval update. The monoclonal antibody therapy provides passive immunity in infants during their first RSV season. Key keywords include RSV prevention, monoclonal antibody, and infant respiratory protection.
Respiratory Syncytial Virus Epidemiology
Recent pipeline analysis highlights rising disease burden and treatment development demand. According to Benjamin J Silk et al., 2026, RSV-associated hospitalization rates reached 1,116.7 per 100,000 in infants aged under 12 months, with estimated 190,000–350,000 hospitalizations and 10,000–23,000 deaths in the United States. Epidemiological trends show seasonal peaks and high-risk pediatric populations. As per Jessy Joseph et al., 2025, RSV positivity rates in India ranged from 2.1%–62.4% among children. Increasing RSV incidence, hospitalization burden, and viral respiratory infection trends are driving innovation in antiviral pipeline development and targeted therapeutic research globally.
Respiratory Syncytial Virus – Pipeline Therapeutic Assessment
This section of the report covers the analysis of respiratory syncytial virus drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase 1)
- Preclinical and Discovery Stage Products
By Drug Class
The respiratory syncytial virus pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Oligonucleotides
- Peptides
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Respiratory Syncytial Virus Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I, at 33%, covers a major share of the total respiratory syncytial virus clinical trials, with strong clinical development and pipeline progression. Phase II is at 32% with robust efficacy evaluation, phase III at 27% supporting late-stage validation and regulatory readiness. Phase IV is at 7% enabling post-approval expansion, while early phase I at 1% with initial research activity, collectively strengthening the respiratory syncytial virus market and accelerating therapeutic innovation globally.
Respiratory Syncytial Virus Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the respiratory syncytial virus pipeline analysis include small molecules, oligonucleotides, and peptides. The respiratory syncytial virus report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for respiratory syncytial virus. Monoclonal antibodies such as ENFLONSIA (clesrovimab-cfor) represent a key RSV prevention biologic therapy, offering long-acting protection in infants. Additionally, fusion inhibitors and RNA-based antivirals are under investigation, aiming to reduce viral replication and improve RSV disease outcomes.
Respiratory Syncytial Virus Clinical Trials – Key Players
The EMR report for the respiratory syncytial virus pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed respiratory syncytial virus therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in respiratory syncytial virus clinical trials:
- Shionogi Inc.
- Pulmotect, Inc.
- Blue Lake Biotechnology Inc.
- ModernaTX, Inc.
- Suzhou Abogen Biosciences Co., Ltd.
- MAXVAX Biotechnology Limited Liability Company
- Sinocelltech Ltd.
- GlaxoSmithKline
- Shanghai Ark Biopharmaceutical Co., Ltd.
- Simcere Pharmaceutical Co., Ltd.
- Guangzhou Patronus Biotech Co., Ltd.
- Pfizer
Respiratory Syncytial Virus – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for respiratory syncytial virus. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of respiratory syncytial virus drug candidates.
Drug: S-337395
S-337395 is an investigational oral, low-molecular-weight antiviral drug being developed for respiratory syncytial virus (RSV) infection and is sponsored by Shionogi. The Phase 2b, multicenter, randomized, double-blind, placebo-controlled study is examining the safety, tolerability, and antiviral efficacy of S-337395 versus placebo in nonhospitalized adults at high risk of progression to severe disease, with treatment initiated within 72 hours of symptom onset. The drug is acting by inhibiting the RNA-dependent RNA polymerase activity of the RSV L protein, thereby blocking viral replication inside infected cells. The study is expected to be completed by December 30, 2026.
Drug: PUL-042
PUL-042 inhalation solution, sponsored by Pulmotect, Inc., is being evaluated in a Phase 2 interventional study examining whether this inhaled, first-in-class combination of two toll-like receptor agonists is reducing the severity of lower respiratory tract infections caused by PIV, hMPV, and RSV in patients with hematologic malignancies and hematopoietic stem cell transplant recipients. The drug is being administered via inhalation to activate the lung epithelial innate immune system, releasing antimicrobial peptides and reactive oxygen species to eliminate pathogens on contact while triggering adaptive immune responses. The study is completing in May 2027 with an overall duration of approximately 30 days.
Biological: BLB-201
BLB-201 (PIV5-vectored RSV vaccine) is a recombinant intranasal vaccine developed by Blue Lake Biotechnology Inc., which is administering a Phase 1/2a randomized, placebo-controlled study (NCT05655182) to evaluate its safety, tolerability, and immunogenicity in infants (8–24 months) and children (18–59 months). The vaccine is being delivered intranasally using a parainfluenza virus type 5 (PIV5) vector encoding the RSV-F protein, which is not known to cause disease in humans and is being used to stimulate mucosal and systemic immune responses against respiratory syncytial virus. The study is examining two ascending doses (10^6 PFU and 10^7 PFU) administered on Day 1, with an additional dose on Day 57 in select cohorts. The trial is expected to be completed by December 2028, as it is evaluating safety, immune response, and dose tolerability in RSV-seronegative and seropositive pediatric populations.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Respiratory Syncytial Virus Pipeline Insight Report
- Which companies/institutions are leading the respiratory syncytial virus drug development?
- Which company is leading the respiratory syncytial virus pipeline development activities?
- What is the current respiratory syncytial virus commercial assessment?
- What are the opportunities and challenges present in the respiratory syncytial virus pipeline landscape?
- What is the efficacy and safety profile of respiratory syncytial virus pipeline drugs?
- Which company is conducting major trials for respiratory syncytial virus drugs?
- Which companies/institutions are involved in respiratory syncytial virus collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in respiratory syncytial virus?
Reasons To Buy This Report
The Respiratory Syncytial Virus pipeline analysis report provides a strategic overview of the latest and future landscape of treatments for respiratory syncytial virus. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into respiratory syncytial virus collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
